[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?

With a market cap of $116.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company focused on developing and commercializing transformative medicines for serious diseases, including cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. It serves patients worldwide through specialty pharmacies, distributors, hospitals, and clinics.

Companies valued at $10 billion or more are generally considered “large-cap” stocks, and Vertex Pharmaceuticals fits this criterion perfectly. The company markets several approved therapies, such as TRIKAFTA/KAFTRIO, ALYFTREK, CASGEVY, and JOURNAVX, while advancing a diverse pipeline of innovative treatments across multiple therapeutic areas. 

Fundamentals

See More
  • Market Capitalization, $K 64,994,552
  • Shares Outstanding, K 105,720
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,629 M
  • EBITDA $ 4,173 M
  • 60-Month Beta 0.30
  • Price/Sales 4.58
  • Price/Cash Flow 14.81
  • Price/Book 2.09

Options Overview Details

View History
  • Implied Volatility 33.91% (+2.58%)
  • Historical Volatility 40.40%
  • IV Percentile 29%
  • IV Rank 33.76%
  • IV High 49.01% on 10/10/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 4) 28.07 (4.66%)
  • Put/Call Vol Ratio 0.29
  • Today's Volume 1,441
  • Volume Avg (30-Day) 1,874
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 42,324
  • Open Int (30-Day) 42,802
  • Expected Range 574.23 to 630.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $8.40
  • Number of Estimates 7
  • High Estimate $11.13
  • Low Estimate $6.29
  • Prior Year $10.72
  • Growth Rate Est. (year over year) -21.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
600.40 +0.05%
on 06/01/26
730.59 -17.78%
on 05/13/26
-100.74 (-14.36%)
since 05/01/26
3-Month
600.40 +0.05%
on 06/01/26
794.77 -24.42%
on 03/03/26
-180.99 (-23.15%)
since 02/27/26
52-Week
476.49 +26.06%
on 06/05/25
821.11 -26.85%
on 01/09/26
+110.39 (+22.52%)
since 05/30/25

Most Recent Stories

More News
Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?

Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

XLV : 147.87 (-1.07%)
VRTX : 438.84 (-1.94%)
REGN : 601.80 (-2.11%)
AMGN : 330.27 (-1.94%)
Is Regeneron Pharmaceuticals Stock Underperforming the Dow?

Regeneron Pharmaceuticals has underperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

VRTX : 438.84 (-1.94%)
$DOWI : 51,085.12 (+0.10%)
REGN : 601.80 (-2.11%)
3 Nasdaq 100 Stocks We Find Risky

3 Nasdaq 100 Stocks We Find Risky

INTC : 109.33 (-4.67%)
KHC : 23.60 (-1.71%)
REGN : 601.80 (-2.11%)
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

Inmazeb ® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically...

REGN : 601.80 (-2.11%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

NEW YORK , May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).  Such investors...

REGN : 601.80 (-2.11%)
Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink?

Regeneron Pharmaceuticals has underperformed the broader market over the past year, and analysts remain reasonably bullish about the stock’s long term prospects.

XLV : 147.87 (-1.07%)
$SPX : 7,607.19 (+0.36%)
REGN : 601.80 (-2.11%)
Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) Over Potential Securities Fraud Allegations

New York, New York--(Newsfile Corp. - May 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.")...

REGN : 601.80 (-2.11%)
Amylyx Stock: Why the Full Pipeline Story Matters

Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares

AMLX : 14.08 (-1.88%)
MRK : 115.17 (-2.99%)
REGN : 601.80 (-2.11%)
Stocks making big moves this week: Toll Brothers, Booz Allen Hamilton, Strategy, Regeneron, and Micron

Stocks making big moves this week: Toll Brothers, Booz Allen Hamilton, Strategy, Regeneron, and Micron

TOL : 138.82 (+0.20%)
MSTR : 149.53 (-6.01%)
MU : 1,033.07 (+6.39%)
BAH : 83.65 (+5.65%)
REGN : 601.80 (-2.11%)
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment...

REGN : 601.80 (-2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 637.61
2nd Resistance Point 631.04
1st Resistance Point 622.91
Last Price 601.80
1st Support Level 608.21
2nd Support Level 601.64
3rd Support Level 593.51

See More

52-Week High 821.11
Fibonacci 61.8% 689.46
Fibonacci 50% 648.80
Fibonacci 38.2% 608.13
Last Price 601.80
52-Week Low 476.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.